MedTrace Logo

Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission

NCT00646126 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2008-03-28

No results posted yet for this study

Summary

The malaria parasite Plasmodium falciparum remains at sub-patent level throughout the dry season in areas of seasonal malaria transmission. Targeting this parasite reservoir before the transmission season could be a good strategy for malaria control. We are conducting a randomized double blind placebo controlled mass drug administration trial in eight village to clear the dry season low level parasitaemia with an ultimate aim of controlling malaria in eastern Sudan.

Conditions

  • Plasmodium Falciparum
  • Asymptomatic Parataemia
  • Sub Patent Parasitaemia

Interventions

DRUG

Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)

Standard three day regimen

DRUG

placebo tablet similar to active drug in shape and size

Dosage similar to active drug(standard three days regimen)

Sponsors & Collaborators

  • London School of Hygiene and Tropical Medicine

    collaborator OTHER

  • International Atomic Energy Agency

    collaborator OTHER_GOV

  • Tropical Medicine Research Institute

    lead OTHER

Principal Investigators

  • Badria B El Sayed, PhD,MSc,BSc · Tropical Medicine Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-08-31

Countries

  • Sudan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00646126 on ClinicalTrials.gov